Assessment of sarcosine vs. placebo impact on schizophrenia symptoms using Positive and Negative Syndrome Scale (PANSS). 6 months [clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6]

Assessment of sarcosine vs. placebo impact on schizophrenia symptoms using Positive and Negative Syndrome Scale (PANSS). 6 months [clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6]

Both arms, every visit
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6
clinicaltrials:NCT01503359
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Assessment of sarcosine vs. placebo impact on schizophrenia symptoms using Positive and Negative Syndrome Scale (PANSS). 6 months [clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6]

Both arms, every visit
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6
Bio2RDF identifier
0a730f46b3333f4118b7536402852ed6
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6
measure [clinicaltrials_vocabulary:measure]
Assessment of sarcosine vs. pl ...... gative Syndrome Scale (PANSS).
time frame [clinicaltrials_vocabulary:time-frame]
description
identifier
clinicaltrials_resource:0a730f46b3333f4118b7536402852ed6
title
Assessment of sarcosine vs. pl ...... ndrome Scale (PANSS). 6 months
@en
inDataset
type
label
Assessment of sarcosine vs. pl ...... 30f46b3333f4118b7536402852ed6]
@en